Trial · NCT00869206
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Skeletal-related Event (SRE) Within 2 Years After Randomization | Arm I (Zoledronic Acid Every 4 Weeks) | 67.6 | percentage of participants | ||
| Percentage of Participants With at Least One Skeletal-related Event (SRE) Within 2 Years After Randomization | Arm II (Zoledronic Acid Every 12 Weeks) | 67.9 | percentage of participants | ||
| Average Pain Intensity Score as Assessed by the Brief Pain Inventory (BPI) Questionnaire | Arm I (Zoledronic Acid Every 4 Weeks) | 2.06 | Standard Error 0.14 | score on a scale | |
| Average Pain Intensity Score as Assessed by the Brief Pain Inventory (BPI) Questionnaire | Arm II (Zoledronic Acid Every 12 Weeks) | 2.09 | Standard Error 0.14 | score on a scale | |
| Average ECOG Performance Status | Arm I (Zoledronic Acid Every 4 Weeks) | 0.82 | Standard Error 0.042 | score on a scale | |
| Average ECOG Performance Status | Arm II (Zoledronic Acid Every 12 Weeks) | 0.84 | Standard Error 0.042 | score on a scale | |
| Incidence of Osteonecrosis of the Jaw | Arm I (Zoledronic Acid Every 4 Weeks) | 2.0 | percentage of participants | ||
| Incidence of Osteonecrosis of the Jaw | Arm II (Zoledronic Acid Every 12 Weeks) | 1.0 | percentage of participants | ||
| Incidence of Renal Dysfunction | Arm I (Zoledronic Acid Every 4 Weeks) | 1.2 | percentage of participants | ||
| Incidence of Renal Dysfunction | Arm II (Zoledronic Acid Every 12 Weeks) | .5 | percentage of participants | ||
| Skeletal Morbidity Rate | Arm I (Zoledronic Acid Every 4 Weeks) | .4 | Standard Deviation 1.0 | SRE's per year | |
| Skeletal Morbidity Rate | Arm II (Zoledronic Acid Every 12 Weeks) | .4 | Standard Deviation 1.1 | SRE's per year | |
| Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Breast Cancer) | Breast Cancer 4 Weeks | Low CTX (<0.415ng/ml) | 83 | Participants | |
| Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Breast Cancer) | Breast Cancer 12 Weeks | Low CTX (<0.415ng/ml) | 75 | Participants | |
| Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Breast Cancer) | Breast Cancer 4 Weeks | High CTX (>0.415ng/ml) | 54 | Participants | |
| Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Breast Cancer) | Breast Cancer 12 Weeks | High CTX (>0.415ng/ml) | 54 | Participants | |
| Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Breast Cancer | Breast Cancer 4 Weeks | 113 | Participants | ||
| Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Breast Cancer | Breast Cancer 12 Weeks | 119 | Participants | ||
| Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Prostate Cancer | Prostate Cancer 4 Weeks | 107 | Participants | ||
| Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Prostate Cancer | Prostate Cancer 12 Weeks | 101 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00869206/results